T-Cell Immunotherapy for Cancer Pipeline Market Analysis Report T-Cell Immunotherapy for Cancer Pipeline Market

T-Cell Immunotherapy for Cancer Pipeline
Market Analysis Report According to Radiant
Insights, Inc
“Cancer is a leading cause of death worldwide.
According to GLOBOCAN 2012, the incidence of
cancer is expected to increase from 14 Million in
2012 to approximately 21 Million by 2030.”
Cancer is a leading cause of death worldwide. According to GLOBOCAN 2012, the incidence of
cancer is expected to increase from 14 Million in 2012 to approximately 21 Million by 2030.
Although conventional therapies, such as chemotherapy and radiotherapy, have been the roots to
slow down the progression of tumors, however till date no complete treatment of this disease is
available in the market. Furthermore, these conventional therapies have numerous side-effects
associated with them, such as nausea, hair loss and abnormal blood cell counts. These limitations
and adverse effects of conventional therapies have therefore created a significant need for the
treatment of cancer. This led to development of new therapies to curb the prevalence of this
disease with minimal side-effects. One such therapy is cancer immunotherapy, particularly T-cell
immunotherapy. T-cell immunotherapy has shown great promise in the treatment of patients with
late-stage cancer.
View summary of this report @ http://www.radiantinsights.com/research/t-cell-
immunotherapy-for-cancer-pipeline-analysis
According to RNCOS' new research report "T-Cell Immunotherapy for Cancer - Pipeline Analysis",
T-cell immunotherapy is one of the most widely researched fields in the recent years. The high
Follow Us: